"In a number of states across the country, there is backlash building against [pharma] sales and marketing," said Ken Johnson, senior VP for the Pharmaceutical Research and Manufacturers of America. "This isn't five years ago. There are new challenges with respect to safety, to sales and marketing, to a wide range of issues. We represent some very smart people that recognize the world doesn't stand still."
The pharmaceutical industry is finally acknowledging that it needs a new marketing prescription after a perfect storm of waning patience in Congress, incredulousness from the medical community and growing angst among a skeptical public.
It's all led the $5 billion direct-to-consumer ad business to concede it has a drug problem.
No comments:
Post a Comment